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ABSTRACT
Aims: Fibrotic sarcoidosis is not common presentation and it is not easy to diagnose for many
differential diagnosis. We herein report an interesting fibrotic sarcoidosis who shows atypical
presentation such as progressive dyspnea with fibrotic imaging findings.
Presentation of Case: A 75-year-old Japanese lady visited our hospital with fifteen months
duration of non-productive cough and one month exertional dyspnea. Physical examination
revealed bilateral fine crackles and squawk at left lung base. Laboratory findings showed elevation
of lactate dehydrogenase (LDH) and Krebs von den Lungen-6 (KL-6). Chest high-resolution
computed tomography (HRCT) showed mediastinal lymphadenopathy, left lower lung field
dominant reticular shadow and traction bronchiectasis. In terms of pulmonary function test (PFT),
percent predicted vital capacity (%VC), forced vital capacity (FVC) and percent predicted forced
vital capacity (%FVC) were 71.2%, 1.12L and 52.8%, respectively. Based on clinical course,
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laboratory findings and chest imaging, we considered possibility of fibrotic non-specific interstitial
pneumonia (f-NSIP).She undertook video-assisted thoracoscopic surgery (VATS). Specimens were
taken from left upper lobe and lower lobe. Pathological findings showed well-formed peri-lymphatic
granuloma, architectural destruction with dense fibrosis and microscopic honeycombing. According
to the clinical-radiological-pathological discussion, we diagnosed this case as fibrotic sarcoidosis.
We commenced oral prednisolone 30 mg/day, treatment response was good including clinical
symptoms, laboratory biomarker and chest imaging findings. She is well on prednisolone 2.5
mg/day now.
Discussion: This case show similar presentation of f-NSIP both clinically and radiologically.
Multidisciplinary discussion was useful for decide to commence adequate management.
Conclusion: We present a fibrotic sarcoidosis patient who mimics f-NSIP.
Keywords: Fibrotic; sarcoidosis; non-specific interstitial pneumonia; Krebs von den Lungen-6;
granuloma.
1. INTRODUCTION
Sarcoidosis is a systemic granulomatous disease
involving eye, lymph nodes, lung, heart and
skin [1]. Japanese sarcoidosis patients often
show eye and heart symptoms such as blurred
vision, chest pain, palpitation and syncope
[2]. Pathogenesis of blurred vision is intraocular
inflammation due to granuloma. In pulmonary
sarcoidosis, African-American patients some-
times have fibrotic process [3]. However,
Japanese sarcoidosis patients usually show
asymptomatic bilateral hilar lymphadenopathy of
chest imaging especially in young man [4,5]. On
the other hand, Japanese elderly woman
sometimes demonstrate symptomatic heart
disease such as complete atrioventricular
block or lung disease [6]. Pulmonary fibrotic
sarcoidosis is unusual in Japan. We herein report
a case of pulmonary fibrotic sarcoidosis patient
who’s clinical symptoms and chest imaging
mimics fibrotic NSIP.
2. PRESENTATION OF CASE
A 75-year-old lady Japanese presented with
fifteen months duration of non-productive
cough and one month exertional dyspnea. Her
medical history was hypertension only, and her
family history including connective tissue disease
(CTD) or interstitial lung disease (ILD) was
unremarkable. She was never smoker. However
her husband was active smoker. Her regular
medication was anti-hypertensive drug and no
other habitual drugs.
She noticed non-productive cough fifteen months
ago. Her local doctor prescribed her anti-tussive,
but her symptom did not improve. In addition,
she developed exertional dyspnea, which
progressively worsened. Her modified medical
research council (mMRC) breathlessnesss score
was 2. Therefore, she was referred to our
hospital. She denied blurred vision, dry eye, dry
mouth, sputum, chest pain, palpitation, joint pain,
muscle ache, rash, fever, appetite loss and body
weight loss.
Findings on our outpatient service: blood
pressure, 184/102 mmHg; heart rate, 106/beat
per minute, regular; respiratory rate, 24/minute;
body temperature, 35.6°C; and SpO2, 95% (roomair). General appearance was not in acute
distress. Her palpebral conjunctiva was not
anemic and bulbar conjunctiva was not icteric.
Oral hygiene was good. Neck showed no
lymphadenopathy. Bilateral fine crackles were
audible at bilateral lung base and squawk was
heard at left lung base. Wheezes was not heard.
Neither heart murmur nor extra heart sound such
as S3 or S4 were observed. There were no
hepatosplenomegaly of note and no edema,
finger clubbing, muscle pain, arthralgia and rash
in extremities.
Laboratory findings on outpatient basis were
elevation of LDH 323 IU/L and KL-6 4761 U/ml.
Inflammation marker such as white blood
cell (WBC) count and C-reactive protein (CRP)
level were within the normal range. Creatine
phosphokinase (CPK) was also negative.
Urinalysis was normal. Autoimmune panel such
as rheumatoid factor (RF), anti-nuclear antibody
(ANA), anti aminoacyl tRNA synthetase (ARS)
antibody, and myeloperoxidase anti-neutrophil
cytoplasmic antibody (MPO-ANCA) were
all negative. In terms of sarcoidosis marker,
angiotensin converting enzyme (ACE) was
negative and soluble interleukin 2 receptor (S-IL-
2 R) was 686 U/ml.
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Fig. 1. Initial chest radiogragh revealed
reticulo nodular shadow in bilateral lower
lung field, volume loss and mediastinal
fullness
Fig. 2. (A) Initial chest CT mediastinal window
showed lymphadenopathy
Fig. 2. (B) Initial chest CT lung window
showed left lung predominant peri-
bronchovascular consolidation, reticular
shadow and traction bronchiectasis without
honeycombing
Chest radiogragh revealed reticulo nodular
shadow in bilateral lower lung field, volume loss
and mediastinal fullness. (Fig. 1) Chest HRCT
showed mediastinal lymphadenopathy and
left lung predominant peri-bronchovascular
consolidation, reticular shadow and
traction bronchiectasis without honeycombing
(Fig. 2A-B).
Low power field H & E
Fig. 3. (A)Specimen from left S3 revealed-
peri-lymphatic granuloma
High power field H & E
Fig. 3. (B)Specimen from left S3 showed well
formed granuloma
PFT showed severe restrictive disorder such
as FVC 1.12 L and % FVC was 52.8%.
Electrocardiogram (ECG) showed normal axis
and no AV block. Based on this information, we
suspected this case as f-NSIP because of lower
lobe predominant fibrotic process without eye
and heart symptoms. And we omit trans
bronchial lung biopsy (TBLB) and broncho
alveolar lavage (BAL) because we thought
sufficient material will be required for definite
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pathological diagnosis. She undertook VATS and
two materials were taken from left S3 and S10.
Pathological findings of S3 showed peri-
lymphatic granuloma (Fig. 3A-B) and S10
revealed granuloma and dense fibrosis
including microscopic honeycombing. (Fig. 4A-B)
Tuberculin skin test was completely
negative. And Galliumscan was negative.
According to the clinical symptoms, radiological
findings and pathological findings, our final
diagnosis was pulmonary fibrotic sarcoidosis. We
commenced oral prednisolone 30 mg/day with
good clinical course. In laboratory findings
serum KL-6 dramatically decreased from 4761
U/ml to 1083 U/ml within three months. And
radiological findings also improved three months
[and one year later. (Fig. 5) In addition, FVC
increased from 1.12L to 1.23L over one year.
Prednisolone dose was gradually tapered to 2.5
mg sixteen months later and she is doing well
now.
Low power field H&E
Fig. 4. (A)Specimen from left S10 revealed
dense fibrosis and granuloma
High power field H&E
Fig. 4. (B)Specimen from left S10 showed
microscopic honeycombing
Fig. 5. Chest CT one year later after treatment
3. DISCUSSION
Our case showed lower lobe predominant
reticular shadow, peri-bronchovascular
consolidation and lower lung field volume loss.
These imaging findings are rather consistent with
anti-ARS syndrome [7,8]. In addition, exertional
dyspnea progressed for one month with severe
restrictive disorder based on PFT. Such subacute
fibrotic lung disease, we usually consider
organizing pneumonia (OP), f-NSIP, subacute
hypersensitivity pneumonia (HP) and drug
induced pneumonia. Clinical point of view, she
had no apparent environment exposure and took
no causative drug including supplement and
herbal medicine. Regarding sarcoidosis, she had
no eye symptoms such as blurred vision, dry eye
and ECG showed normal findings [9]. Therefore,
typical Japanese sarcoidosis presentation were
absent. Most common sign and symptoms of
Japanese typical sarcoidosis patient are neck
lymphadenopathy, blurred vision and palpitation.
In addition, her chest HRCT findings revealed no
upper lung field predominance and granular
shadow. Only consistent findings of sarcoidosis
was mediastinal lymphadenopathy [10]. Based
on these information, our most possible
diagnosis before biopsy was f-NSIP or fibrosing
organizing pneumonia (fOP) [11]. Pathological
findings showed peri-lymphatic well formed
granuloma, dense fibrosis and architectural
destruction such as microscopic honeycombing
especially lower lung field. According to the 2011
idiopathic pulmonary fibrosis (IPF) guideline,
our case was not pathological usual interstitial
pneumonia (UIP) [12]. Through clinical
radiological pathological discussion, we arrived
at pulmonary fibrotic sarcoidosis [13]. Other
interesting findings was marked elevation of her
serum KL-6. KL-6 is a high-molecular weight
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protein and useful marker of fibrotic lung disease
[14]. However, serum ACE is more often
elevated in sarcoidosis patients [15,16]. With
pathological findings, our case had repetitive
extensive injury of alveolar type Ⅱcell and more
fibrotic area than granuloma volume. This
findings was accordance with negative findings
of Ga scan [17]. In typical Japanese sarcoidosis
patient, only bilateral hilum lymphadenopathy
was seen without symptom. General indication of
systemic prednisolone are cardiac, neurogenic
and fibrotic sarcoidosis. After starting treatment
based on definite diagnosis of fibrotic
sarcoidosis,our case showed good response
including clinical symptoms, laboratory data, PFT
and radiological findings. However, pulmonary
fibrotic sarcoidosis patients often show persistent
symptoms and poor survival. Therefore,we
should monitor this case carefully indefinitely
because of poor pulmonary function and
pathological dense fibrosis which suggest non-
favorable prognosis.
4. CONCLUSION
We report a case of pulmonary fibrotic
sarcoidosis patient who mimics f-NSIP. So,
multi disciplinary discussion including physician,
radiologist and pathologist is important for
providing adequate management of atypical
fibrotic lung disease.
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